



## **IBA reaches major milestones on compact proton therapy technologies, confirming momentum on *Proteus<sup>®</sup>ONE***

**Louvain-la-Neuve (Belgium), Shreveport (Louisiana, US), May 7, 2013** — IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, is pleased to announce that it has reached major milestones in the development of its new, compact and affordable proton therapy solution, *Proteus<sup>®</sup>ONE*<sup>1</sup>. The *Proteus<sup>®</sup>ONE* system, which includes a compact gantry and compact synchrocyclotron, allows much greater access to proton therapy given the system is easier to install and operate and is also more easily financeable.

The IBA Compact Gantry is a break-through device that will allow for unparalleled treatment quality both in terms of precision and care for patients. Its unique Energy Selection and Scanning Systems will create the sharpest and most precise beam distributions. The patient centric design will allow for unprecedented access to the patient and comfort. This gantry is entering into final testing stages before shipping to the Willis Knighton Cancer Center, in Shreveport, Louisiana, USA.

The IBA Compact Synchrocyclotron answers to the needs for smaller and more energy-efficient devices in the proton therapy market. This accelerator has now reached the specifications required in terms of Field Strength and Stability, Current Dynamics and Radio-Frequency acceleration performances. This accelerator will be shipped later this year to the Centre Antoine Lacassagne (CAL) in Nice, France.

These two revolutionary technologies will be combined with the 20+ years of experience encompassed in the IBA Proteus technology, to form the most advanced compact Intensity Modulated Proton Therapy (IMPT) capable system in the world. The first patient's to benefit from this technology are expected to be treated in 2014.

**Olivier Legrain, Chief Executive Officer of IBA**, said: *"Proteus<sup>®</sup>ONE represents a solution to further reduce the costs and complexity of proton therapy, helping to reduce the technological and financial risk for our stakeholders. IBA's extensive experience of the market and world leading technology makes IBA the best choice in the market today. With Proteus<sup>®</sup>ONE, proton therapy becomes an achievable reality for more patients worldwide."*

The IBA Proteus technology is today planned or utilized in 25 centers around the world, 14 are treating patients every day. Its compact version, *Proteus<sup>®</sup>ONE* is the safest path to bring compact Intensity Modulated Proton Therapy (IMPT) to the integrated Cancer Center at the Willis Knighton Cancer Center (WKCC), Shreveport, Louisiana.

---

<sup>1</sup> *ProteusONE* is the brand name of a new configuration of the Proteus 235 including some new developments subject to review by competent authorities (FDA, Notified bodies, et al.) before marketing.



**Lane R. Rosen, MD, Director of Radiation Oncology at WKCC,** added: *“The treatment vault and planning areas are only one-fifth of our new Cancer Center construction footprint, which highlights how compact the system is. Having all types of treatment modalities in one place will allow us to integrate therapies and make treatment more convenient.*

*“I can definitely see a role for a proton boost as part of the conventional RT treatments as a way to minimize side effects while keeping costs reasonable. We’re looking forward to making proton therapy a reality for more patients.”*

IBA is committed to making Proton Therapy, the most accurate cancer treatment, available worldwide. IBA is the only supplier to have multiple centers treating cancer patients with Pencil Beam Scanning (PBS), the most precise form of Proton Therapy. PBS enables Intensity Modulated Proton Therapy (IMPT), allowing clinicians to precisely target a cancerous tumor by controlling both the intensity and the spatial distribution of the dose to the millimeter.

### **About Proteus<sup>®</sup> ONE<sup>2</sup>**

IBA Proteus<sup>®</sup> ONE is a compact single-room proton therapy solution. It benefits from the latest technologies of Proteus<sup>®</sup> PLUS that have been developed with top clinical institutions worldwide. Proteus<sup>®</sup> ONE is designed to bridge the gap between conventional radiotherapy and proton therapy. Proteus<sup>®</sup> ONE offers IMPT enabling physicians to leverage completely on the clinical effectiveness of Proton Therapy. Proteus<sup>®</sup> ONE has been inspired by everyday clinical practice. Its design, developed in collaboration with Philips enhances the patient and staff experience by fostering a soothing environment making therapy safer and easier.

With Proteus<sup>®</sup> ONE, protons are possible for more patients worldwide. [www.iba-proteusone.com](http://www.iba-proteusone.com)

### **About Proton Therapy**

Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and sparing healthy surrounding tissue.

As access to proton therapy increases in Europe and across the world, IBA continues to demonstrate compassionate innovations with more patient-friendly treatment rooms and more precise therapies. IBA proton therapy systems account for more than half of the world’s clinically based proton therapy facilities. To date they include 13 operational proton therapy centers worldwide, and 12 more centers in development.

### **About IBA**

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company’s expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA’s leading fully integrated IntegraLab<sup>®</sup> radiopharmacy

---

<sup>2</sup> Proteus ONE is the brand name of a new configuration of the Proteus 235 including some new developments subject to review by competent authorities (FDA, Notified bodies, et al.) before marketing.



system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets.

The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

## **Contact**

### **Olivier de Sadeleer**

**IBA**

Marketing Manager, Proton Therapy

Phone : +32 10 203 342

E-mail. [Olivier.deSadeleer@iba-group.com](mailto:Olivier.deSadeleer@iba-group.com)

### **Thomas Ralet**

**IBA**

Vice-President Corporate Communication

+32 10 475 890

[communication@iba-group.com](mailto:communication@iba-group.com)

### **For media and investor enquiries:**

#### **M:Communications**

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson

+44 (0) 207 920 2333

[IBA@mcomgroup.com](mailto:IBA@mcomgroup.com)